Actelion, Auxilium partner to build up and commercialize XIAFLEX Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd . (SWX: ATLN. Actelion will be primarily responsible for the applicable regulatory and commercialization activities for XIAFLEX in these national countries. XIAFLEX has been accepted by the U.S. Food and Drug Administration and the European Medicines Agency as a treatment for Dupuytren’s contracture, and is in advancement in Japan also. In addition, XIAFLEX has been accepted for review by Wellness Canada for the treating Dupuytren’s contracture in Canada and regulatory actions is expected in the second half of 2012.